Tracheal, bronchus, and lung (TBL) cancer contributes significantly to the disease burden globally, increasing expenditure on health and impacting the quality of life. According to estimates, TBL cancer resulted in over two million deaths in 2019 alone. The incidence, mortality, and disability-adjusted life years (DALYs), defined as the number of healthy years lost due to disease, vary widely across regions and time, contributing to geographical disparities in TBL patterns globally. These geographical and temporal variations in TBL cancer burden patterns may be attributed to variations in exposure to risk factors like smoking, genetic predisposition, or health coverage.
While countries have made concerted efforts to reduce TBL burden, the severity of demographic challenges and exposure to multiple risk factors continues to remain a concern. In a study recently published in the Chinese Medical Journal Pulmonary and Critical Care Medicine online on 28 March 2023, researchers from China have now uncovered geographical and temporal patterns in TBL burden for the period between 1990–2019. The study, led by Professor Ni Li from the Chinese Academy of Medical Sciences and Peking Union Medical College in China, used data from the Global Burden of Disease (GBD) study, which covers disease trends across 204 countries and territories.
For examining the geographical trends in TBL burden, the team investigated the variations in TBL cancer burden across four income regions defined by the World Bank – high-income countries (HICs), upper-middle-income countries (UMCs), lower-middle-income countries (LMCs), and low-income countries (LICs). Additionally, for examining the temporal trends, they looked at annual percentage changes to the age-standardized incidence rate (ASIR), the age-standardized mortality rate (ASMR), and the age-standardized DALY rate (ASDR).
The study revealed that while TBL cancer burden decreased from 1990 to 2019 globally, there were notable variations across regions and countries. Explaining these findings further, Prof. Li says, "Globally, approximately 2,260,000 new TBL cancer cases, 2,042,600 deaths, and 45,858,000 DALYs were reported in 2019. We observed a decreasing trend in the TBL cancer burden in most of the 21 GBD regions and 204 countries from 1990 to 2019." The downward trend of the TBL burden was also reflected in its constituent measures – ASIR, ASMR, and ASDR – all of which decreased between 1990–2019 globally.
Moreover, the decline in ASIR, ASMR, and ASDR of TBL cancers was most prominent in HICs. In contrast, UMCs experienced the greatest increases in ASIR and ASMR and reported the highest TBL cancer burden in 2019. "Eastern Europe experienced the largest mean decrease per year in ASIR, ASMR, and ASDR of TBL cancer over the study period, while Central Europe had the greatest behavioral risk-attributable DALY," highlights Prof. Li. Of the 204 countries included in the study, the ASIR, ASMR, and ASDR of TBL cancer reflected decreasing trends in 85, 91, and 104 countries, respectively, with the largest decrease recorded in Bahrain.
Furthermore, the researchers also looked at the association between universal health coverage and the TBL cancer burden at the national level. They found geographic disparities in access to health care, pointing to the need for future interventions for early prevention and control of TBL cancer. Notably, there were contrasting trends in ASIR and ASMR of TBL cancer among UMCs compared with that of HICs and LMCs. This was attributed to discrepancies in epidemiological and demographic transitions.
Overall, these results uncover the differences in temporal trends and spatial distribution of TBL cancer burden over two decades and across the world, and underscore the need for improved screening and diagnostic techniques as well as availability of health resources among different income-classified regions.
Going ahead, these findings could provide a valuable roadmap for understanding the trends in TBL cancer burden across regions to help deliver tailored interventions for mitigating them.
***
Reference
DOI: https://doi.org/10.1016/j.pccm.2023.02.001
Authors: Chenran Wang1, Zheng Wu1, Yongjie Xu1, Yadi Zheng1, Zilin Luo1, Wei Cao1, Fei Wang1, Xuesi Dong1, Chao Qin1, Liang Zhao1, Changfa Xia1, Fengwei Tan2, Wanqing Chen1, Ni Li1,3, and Jie He2
Affiliations:
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
3Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implementation, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
About Professor Ni Li
Ni Li is currently a Professor at the Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, China. Additionally, she also serves as a Professor at the Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implementation, Chinese Academy of Medical Sciences and Peking Union Medical College. Prof. Li specializes in cancer epidemiology and prevention and has published over 20 scientific articles. Her research relates to a range of subjects, including lung neoplasms, international trends in disease burden, human papillomavirus, and sleep science.
